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OBJECTIVE—It has been shown that vascular progenitors from
patients with diabetes are dysfunctional. However, therapeutic
strategies to counteract their reduced functional capacity are still
lacking. Because adiponectin has reported salutary effects on
endothelial function, we investigated the functional effects of
globular adiponectin (gAcrp), the active domain of adiponectin,
on isolated endothelial colony-forming cells (ECFC).
RESEARCH DESIGN AND METHODS—ECFC were isolated
from peripheral blood of type 2 diabetic patients (dmECFC) and
compared with ECFC of healthy young volunteers (yECFC) and
nondiabetic age-matched control subjects (hECFC). Cells were
treated with gAcrp for 48 h followed by assessment of cell counts,
cell cycle analysis, and migration capacity. For in vivo evaluation,
human ECFC were injected into normoglycemic or streptozotocin-
induced hyperglycemic nu/nu mice after hind limb ischemia.
RESULTS—Whereas dmECFC were functionally impaired com-
pared with yECFC and hECFC, gAcrp signiﬁcantly enhanced
their in vitro proliferation and migratory activity. In vitro effects
were signiﬁcantly stronger in hECFC compared with dmECFC
and were mediated through the cyclooxygenase-2 pathway. Most
important, however, we observed a profound and sustained
increase of the in vivo neovascularization in mice receiving
gAcrp-pretreated dmECFC compared with untreated dmECFC
under both normoglycemic and hyperglycemic conditions.
CONCLUSIONS—Pretreatment of ECFC with gAcrp enhanced
the functional capacity of ECFC in vitro and in vivo in
normoglycemic and hyperglycemic environments. Therefore,
preconditioning of dmECFC with gAcrp may be a novel approach
to counteract their functional impairment in diabetes. Diabetes
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ardiovascular disease leading to coronary artery
disease and stroke remains the most frequent
cause of death in patients with diabetes melli-
tus, whereas impaired perfusion of the extrem-
ities leads to foot ulcers and amputations resulting in high
morbidity and subsequent socioeconomic burden (1).
Emerging evidence from experimental and early clinical
studies suggests that endothelial progenitors, mobilized
from the bone marrow into peripheral blood, travel to sites
of tissue injury, and contribute to neovascularization,
thereby improving blood ﬂow and promoting tissue re-
generation (2–4). Although bone marrow and peripheral
blood-derived endothelial progenitors have convincingly
been shown to improve neovascularization in different
experimental and clinical settings, the clinical utility of so-
called early endothelial progenitors is still limited because
of their low proliferation rate and a rather monocytic
phenotype (5–11).
In contrast, endothelial colony-forming cells (ECFC),
a highly homogeneous subpopulation of endothelial pro-
genitors, bear a high proliferative capacity and strong en-
dothelial commitment (9). ECFC can be derived from cord
blood and peripheral blood of healthy donors or patients
and are therefore more suitable for cell-based vascular
regeneration. Although cord blood-derived ECFC demon-
strate a high proliferative capacity compared with pe-
ripheral blood-derived ECFC, their clinical use is limited
by the need for immunosuppressive therapy. On the other
hand, progenitors isolated from patients with cardiovascu-
lar risk factors including diabetes are limited in numbers,
dysfunctional, and linked to impaired vascular homeostasis
and vascular function (12–14). In addition, endothelial pro-
genitor cells (EPC) are also functionally impaired in re-
sponse to high glucose levels in vitro (15–17). Therefore,
cell therapeutic approaches taking advantage of the neo-
vascularization capacity of autologous endothelial progeni-
tors have to include strategies aiming for the restoration of
the impaired functional capacity of diabetic patient-derived
endothelial progenitors before their in vivo administration.
Several studies reported a close association between
circulating levels of adiponectin, a hormone originating
from adipocytes (also known as adipocyte complement-
related protein of 30 kDa [Acrp30]), and type 2 diabetes
mellitus. While lower serum adiponectin levels were
found in type 2 diabetes (18), people with high serum
adiponectin concentrations are at lower risk for developing
diabetes (19,20), and increasing adiponectin concen-
trations are linked to a lower incidence of developing
insulin-resistance and type 2 diabetes (21–23). Therefore,
we examined the effects of treating type 2 diabetic patient-
derived ECFC with the active domain of adiponectin, termed
“globular adiponectin” (gAcrp), with respect to their number
and function. We found that gAcrp is an effective in vitro
pretreatment modality to functionally rescue type 2 diabetic
patient-derived ECFC for advanced in vivo cell therapy
applications. Most important, this pretreatment effect was
also preserved in hyperglycemic mice with hind limb
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ORIGINAL ARTICLEischemia, further emphasizing the clinical relevance of this
novel approach.
RESEARCH DESIGN AND METHODS
Isolation of human progenitor cells. Peripheral blood was obtained after
informed consent from type 2 diabetic patients with A1C .7.5% (n = 8; male
and postmenopausal female, age 60 6 5.8 years), nondiabetic age-matched
control subjects (n = 5; male and postmenopausal female, 66 6 3.6 years)
(Table 1), and young healthy subjects (n = 5; male, age 26.4 6 0.8 years) as
a source for fully functional ECFC as positive controls. ECFC were isolated
from peripheral blood by Ficoll density-gradient centrifugation as previously
described (24). Brieﬂy, mononuclear cells were cultured in 6-well tissue cul-
ture plates precoated with type 1 rat tail collagen (BD Biosciences, Bedford,
MA) with endothelial basal medium-2 supplemented with 10% FBS and EGM-2
SingleQuots (human epidermal growth factor, human ﬁbroblast growth factor-B,
vascular endothelial growth factor [VEGF], ascorbic acid, hydrocortisone,
Long R3-IGF-1, heparin, gentamicin/amphotericin). After 24 h, nonadherent
cells and debris were removed. Medium was changed daily during the ﬁrst
7 days and then every other day until colonies appeared. Colonies were picked
and further expanded for the experiments. Expanded cells were then pre-
treated with control or human recombinant gAcrp30 (1 mg/mL; Peprotech,
Hamburg, Germany) in the presence or absence of parecoxib (100 mmol/L;
Dynastat; Pﬁzer Inc., New York, NY) and superoxide dismutase (SOD)
(300 units/mL; Sigma, Steinheim, Germany), respectively, during the ﬁnal 48 h.
To assess population-doubling times, ECFC derived from type 2 diabetic
patients or healthy donors were cultured for at least 25 days. Cells were
regularly split at 80% conﬂuence, cell numbers were counted, and 500,000 cells
were replated in a fresh dish. Population doubling time was calculated as
follows: Td =( t 2 2 t1) 3 log(2)/log(q2/q1); (Td: population doubling time;
t2: end-time point; t1: start-time point; q2: end population size; q1: start pop-
ulation size).
Flow cytometry. Surface expression of CD31, CD34, and VEGF receptor 2
(VEGFR-2) was assessed by ﬂow cytometry. Cells were preincubated with
Flebogamma (Grifols, Langen, Germany) to prevent unspeciﬁcb i n d i n go f
antibodies and were stained using antibodies against CD31, CD34 (both eBio-
science, San Diego, CA) and VEGFR-2 (ReliaTech, Wolfenbüttel, Germany).
Each analysis included 10
5 gated events. Cell cycle analysis was performed
using a BrdU Flow Kit (BD Biosciences) according to the manufacturer’s
instructions. Cells were pulsed with BrdU for 2 h. All samples were analyzed
using a FACSCalibur, and data were analyzed with CELLQuest Pro software
(both BD Biosciences) or FlowJo (Tree Star, Ashland, Oregon).
mRNA expression. For the detection of the speciﬁc adiponectin receptors
AdipoR1 and AdipoR2, total RNA from both healthy donors and diabetic
patient-derived ECFC was isolated using the RNeasy kit (Qiagen, Hilden,
Germany). Quantiﬁcation of AdipoR1 and AdipoR2 mRNA was performed by
RT-PCR of 100 ng RNA using previously described primers (25).
Knock-down of AdipoR1 and AdipoR2. To determine the functional rele-
vance of AdipoR1 and AdipoR2, we transfected ECFC with Accell small in-
terfering (si)RNA (Thermo Scientiﬁc, Waltham, MA) for AdipoR1 or AdipoR2
according to the manufacturer’s instructions. Then, changes in cell numbers in
response to gAcrp were assessed.
Assessment of in vitro migratory capacity of progenitor cells. Cells were
pretreated for 48 h with 1 mg/mL gAcrp, 100 mmol/L parecoxib, 300 units/mL
SOD, or combinations of those. A total of 5 3 10
5 cells each was resuspended
in 250 mL Dulbecco’s modiﬁed Eagle’s medium + 5% FCS and placed in the
upper chamber of a modiﬁed Boyden chamber ﬁlled with Matrigel (BioCoat
invasion assay, 8-mm pore size, BD Biosciences). The upper chamber was
placed in a 24-well culture dish containing 500 mL EGM-2. After 12 hours of
incubation at 37°C with 5% CO2, transmigrated cells were stained with di
aminido phenyl indol, and 4–6 separate visual ﬁelds were recorded with an
AxioScope 40 with AxioCam MRc 5 (Carl Zeiss, Jena, Germany) at 103
magniﬁcation and counted with ImageJ (National Institutes of Health,
Bethesda, MD).
Live imaging of superoxide production in vitro. Cells were stimulated for
12 h with 1 mg/mL gAcrp and incubated with MitoSOX Red (Invitrogen, Bar-
celona, Spain; 5 mmol/L) for 10 min before analysis. Levels of mitochondrial
superoxide in the presence or absence of gAcrp were measured by quantiﬁ-
cation of MitoSOX Red intensity using a Leica SP2 confocal microscope
(Leica, Wetzlar, Germany).
Measurement of prostaglandin E2 and nitric oxide levels in cell culture
supernatants. To determine levels of prostaglandin E2 (PGE2) and nitric
oxide, we used a PGE2 ELISA (Cayman Chemical, Ann Arbor, MI) and
a ﬂuorometric nitric oxide assay kit (Biovision, Mountain View, CA), re-
spectively, according to the manufacturers’ instructions.
Animal models. All animal experiments were conducted in accordance with
institutional guidelines and approved by the Institutional Animal Care and Use
Committee of the Centro Nacional de Investigaciones Oncológicas and by the
Administrative Panel on Laboratory Animal Care (Government of Upper
Bavaria, Germany). Female athymic NMRI nu/nu mice (Janvier, Le Genest-
Saint-Isle, France) were used. For induction of diabetes, animals were treated
according to the low-dose streptozotocin induction protocol of the Animal
Models of Diabetic Complications Consortium. Brieﬂy, animals were fasted for
4 h and afterward intraperitoneally injected with streptozotocin (50 mg/kg;
Sigma). This procedure was repeated daily for 5 days. On day 28, hypergly-
cemia was conﬁrmed by urine glucose analyses with Combur 10 urine test
strips (Roche, Grenzach-Wyhlen, Germany). Only animals with a minimum
glucose grade of 3+ (.750 mg/dL) were used for experiments.
Normoglycemic and hyperglycemic mice were subjected to hind limb
ischemia followed by intravenous administration of human progenitor cells
(5 3 10
5 cells per mouse) (26) after 24 h. To achieve hind limb ischemia, the
proximal portion of the right femoral artery, including the superﬁcial and deep
branches, was irreversibly disrupted using electrical coagulation. The over-
lying skin was closed using surgical staples. After 1 and 2 weeks, respectively,
limb perfusion in the ischemic (right) and nonischemic (left) limb was
assessed using an O2C laser Doppler blood ﬂow analyzer with a LFM-2 micro
probe (2 mm tissue penetration; Lea Medizintechnik, Giessen, Germany).
Before analysis, mice were placed on a heating pad at 37°C to minimize var-
iations in ambient temperature. Relative perfusion was calculated as the ratio
of blood ﬂow in the ischemic and nonischemic limbs. Furthermore, we
assessed the blood ﬂow by intravital near-infrared ﬂuorescence imaging (27).
After intravenous injection of the near-infrared ﬂuorophore indocyanine green
(Sigma), images were obtained by an In Vivo Imaging System-200 (Caliper Life
Sciences, Hopkinton, MA) and analyzed using Living Image 3.2.
Statistical analysis. Results for continuous variables are expressed as
means 6 SEM. Overall comparison of continuous variables was performed
with the Kruskal-Wallis test followed by post hoc pairwise comparison using
the Mann-Whitney test. Comparison of categoric variables was done using the
Pearson x
2 test. P , 0.05 was considered statistically signiﬁcant. All analyses
were performed with SPSS 16.0 (SPSS Inc., Chicago, IL).
RESULTS
Reduced population doubling time in type 2 diabetic
patient-derived ECFC. First, we determined differences
in proliferation between diabetic ECFC (dmECFC) and
TABLE 1
Patient characteristics of diabetic patients and age-matched
nondiabetic control subjects
Nondiabetic
control subjects;
n =5
Diabetic
patients;
n =8 P value
Height (m) 1.69 6 0.05 1.72 6 0.03 NS
Weight (kg) 75.6 6 6.1 103 6 7.9 NS
BMI (kg/m
2) 26.3 6 1.3 34.9 6 2.4 0.03
Age (years) 66 6 3.6 60 6 5.5 NS
Hypertension 3 (60%) 7 (88%) NS
Hypercholesterinemia 3 (60%) 6 (75%) NS
Hypertriglyceridemia 0 (0%) 3 (38%) NS
CAD 0 (0%) 1 (13%) NS
MI 0 (0%) 0 (0%) —
PAD 0 (0%) 0 (0%) —
Stroke 0 (0%) 1 (13%) NS
Renal insufﬁciency 0 (0%) 1 (13%) NS
Antidiabetic
medication 0 (0%) 8 (100%) 0.001
Antihypertensive
medication 3 (60%) 6 (75%) NS
Lipid-lowering
medication 1 (20%) 3 (38%) NS
Results for continuous variables are expressed as means 6 SEM.
Comparisons between groups were analyzed by the nonparametric
Mann-Whitney U test. Comparison of categoric variables was tested
by the Pearson x
2 test. CAD, coronary artery disease; MI, myocardial
infarction; PAD, peripheral artery disease.
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as maximally functional positive controls. To assess
population doubling time, we kept ECFC in culture over a
period of 1 month. Cells were passaged and cell numbers
were recorded during splitting of the cells every time cells
had reached 80% conﬂuency. After only 5 days, yECFC were
already doubled in numbers compared with dmECFC. On
day 15, the population of yECFC exceeded that of dmECFC
by 2.9-fold, followed by 3.2-fold excess after 25 days. The
resulting calculated population doubling time was 6.7 days
for dmECFC compared with 4.6 days for yECFC (P , 0.05)
(Fig. 1A). We did not ﬁnd signiﬁcant functional differ-
ences between yECFC and ECFC derived from aged, but
nondiabetic individuals (hECFC) as assessed by cell num-
bers after 48 h of culture (Fig. 1B). Because the baseline
characteristics of donors for hECFC and dmECFC only
signiﬁcantly differed for BMI and antidiabetic medication
(Table 1), these data are consistent with the hypothesis
that the impaired function of dmECFC is most likely re-
lated to the diabetic environment.
Phenotypic evaluation of hECFC and dmECFC. By
conventional microscopy, dmECFC showed a similar gross
morphology compared with hECFC and previously de-
scribed cord-blood derived ECFC (9) (Supplementary Fig.
1A). As assessed by ﬂow cytometry, expression of the
endothelial markers CD31 and VEGFR-2, as well as the
FIG. 1. Characterization of nondiabetic ECFC vs. diabetic ECFC. A: Proliferation of yECFC (white squares; n = 5) and dmECFC (black diamonds;
n = 4) was compared by population doubling curves (P < 0.01 dmECFC vs. yECFC). B: Cell numbers for yECFC (n = 5), hECFC (n = 3), and
dmECFC (n = 8) compared after 48 h in culture.
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Fig. 1B) and unchanged over a period of 1 month in both
diabetic dmECFC and nondiabetic hECFC (Supplementary
Fig. 1C).
gAcrp stimulates ECFC proliferation. Next, we in-
vestigated the effects of gAcrp pretreatment on the pro-
liferative capacity of ECFC. In vitro pretreatment with
gAcrp for 48 h led to a signiﬁcant increase in cell numbers
for nondiabetic age-matched control subjects (hECFC)
(48.4 6 14.1% increase compared with control treated
hECFC) and dmECFC (18 6 2.5% increase compared with
control treated dmECFC) (Fig. 2A). Therefore, ECFC
derived from hyperglycemic patients were signiﬁcantly
(P , 0.05) less responsive to gAcrp treatment compared
with ECFC derived from normoglycemic environments. To
investigate the speciﬁc mechanism of the modestly higher
yield of dmECFC in the gAcrp-treated group, we performed
cell cycle analyses. Stimulation with gAcrp increased the
fraction of dmECFC in S-phase to 195.4 6 48.5% of control
(P , 0.05, Fig. 2B and C).
Mechanisms of impaired proliferation of dmECFC.
First, we examined whether hECFC and dmECFC are
similarly endowed with the speciﬁc adiponectin receptors
AdipoR1 and AdipoR2 by RT-PCR (28). Indeed, hECFC
and dmECFC both express AdipoR1 and AdipoR2 at sim-
ilar and comparably high levels, which also did not differ
from the expression levels of yECFC (Supplementary Fig.
2). Therefore, we investigated the effects of gAcrp on ex-
pansion of ECFC in vitro. To elucidate mechanisms un-
derlying the reduced response of dmECFC to gAcrp
compared with hECFC, we ﬁrst validated that adiponectin
receptors are operative in dmECFC. For this purpose, we
silenced AdipoR1 and AdipoR2 mRNA by speciﬁc small
interfering RNA (Fig. 3A). Silencing of the individual
adiponectin receptors AdipoR1 or AdipoR2 or a combina-
tion of those resulted in a signiﬁcant decrease in cell
numbers (P , 0.05), which could not be reversed by gAcrp
treatment. These data conﬁrm that dmECFC express func-
tional adiponectin receptors AdipoR1 or AdipoR2. Then, we
focused on enhanced oxidative stress as a mechanism of
impaired gAcrp response in dmECFC because EPC dys-
function in patients with type 2 diabetes has been linked to
excessive generation of reactive oxygen species (29). To
compensate the less pronounced stimulatory effect of
gAcrp on dmECFC compared with hECFC, we also treated
the cells with SOD to reduce oxidative stress. Indeed,
whereas SOD alone had no effects on dmECFC yield, SOD
pretreatment resulted in enhanced stimulation of dmECFC
(33.5 6 8.7% increase in SOD + gAcrp) (Fig. 3B). To clarify
the effect of gAcrp administration on oxidative stress in
ECFC, we pretreated hECFC and dmECFC for 12 h with
gAcrp and performed live imaging of the intracellular pro-
duction of superoxide anions using MitoSOX Red (Fig. 3C).
Quantiﬁcation of the signal intensity demonstrated that
pretreatment with gAcrp signiﬁcantly reduced superoxide
levels in diabetic ECFC (P , 0.01). Therefore, we conclude
that the effects of gAcrp in dmECFC are at least in part
superoxide-dependent/related.
Furthermore, adiponectin has been reported to induce
activation of the cyclooxygenase 2 (COX-2) pathway and
subsequently promotes PGE2 synthesis in stromal cells
(30). We consistently show that gAcrp induces PGE2 pro-
duction (Fig. 3D). We recently demonstrated that PGE2
stimulates proliferation and function of EPC, an effect
that was abrogated after inhibition of COX-2 (31). Thus,
we hypothesized that gAcrp-induced effects in ECFC are
mediated via the COX-2 pathway. Administration of the
selective COX-2 inhibitor parecoxib alone had no effects
on cell proliferation, but potently blocked the gAcrp-
mediated increase in cell numbers when simultaneously
FIG. 2. Effect of pretreatment with gAcrp on ECFC numbers and pro-
liferation. A: Cell numbers for hECFC (n = 3) and dmECFC (n = 8) after
stimulation with 1 mg/mL gAcrp given as difference between gAcrp
treatment and PBS control group (*P < 0.05 vs. control, **P < 0.05 vs.
dmECFC and control). B: Proliferation measured as BrdU in-
corporation after stimulation with gAcrp (n =3 ,* P < 0.05). C: Repre-
sentative pictures of the gating strategy used for the evaluation of
BrdU incorporation by ﬂow cytometry. Upper: control. Lower: gAcrp
stimulation.
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diabetes.diabetesjournals.org DIABETES, VOL. 60, FEBRUARY 2011 655FIG. 3. Mechanism of reduced gAcrp response in dmECFC. A: Expression of functional adiponectin receptors on dmECFC cells. Selective silencing
of AdipoR1 and AdipoR2 was performed using small interfering RNA. Stimulation of the cells by gAcrp was assessed as ECFC yield (*P < 0.05 vs.
control, **P < 0.05 vs. gArcp, §P < 0.05 vs. AdipoR1 + AdipoR2 + gArcp, §§P < 0.05 vs. AdipoR1 + gArcp and AdipoR2 + gArcp, n =3 ) .B: Effect of
treatment of dmECFC with gAcrp (n =7 ) ,S O D( n = 4), parecoxib (n = 6), alone or in combination with gAcrp on cell numbers, given as difference
between treatment groups and PBS control (*P < 0.001 vs. control; **P < 0.05; ***P < 0.01 vs. control, P < 0.05 vs. gAcrp). C: Effect of pre-
treatment with gAcrp on intracellular superoxide production in ECFC. Representative live images (left) of untreated or gAcrp-treated hECFC and
dmECFC after incubation with MitoSOX Red and quantiﬁcation of MitoSOX Red intensity (right)( * P < 0.01 vs. control, n =3 ) .D: Production of
PGE2 in supernatants of dmECFC treated with or without gAcrp as measured by ELISA. *P < 0.01 vs. control. E: Migratory activity of ECFC after
gAcrp (n = 4) preconditioning of dmECFC in the presence or absence of SOD or parecoxib (each n = 3), given as difference between treatment
groups and PBS control. The last white bar shows comparison with hECFC treated with gAcrp (*P < 0.01 vs. control; **P < 0.05 vs. gAcrp, n =3 ) .
Representative images for migrated dmECFC pretreated with control (upper right) or gAcrp (lower right). (A high-quality color representation of
this ﬁgure is available in the online issue.)
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s t i m u l a t o r ye f f e c to fg A c r pi sa tl e a s ti np a r tm e d i a t e dv i a
the COX-2 pathway. Moreover, we recently showed that
prostaglandin E1 and PGE2 stimulate progenitor cell pro-
liferation and function via induction of endothelial nitric
oxide synthase (eNOS) (31). To investigate whether gAcrp-
induced ECFC numbers might be dependent on the eNOS
pathway, we collected supernatants for a ﬂuorometric nitric
oxide assay demonstrating that gAcrp treatment results in
as i g n i ﬁcant increase in nitrite levels indicative for en-
hanced nitric oxide production (142.2 6 21.8% control,
P , 0.05, Supplementary Fig. 3). Therefore, we provide
evidence that gAcrp directly stimulates nitric oxide pro-
duction, which suggests involvement of the eNOS pathway
in gAcrp-induced functional improvements of diabetic
patient-derived ECFC.
gAcrp stimulation enhances migratory activity of
ECFC. Migration is a key feature of EPC crucial for
their in vivo cell therapeutic effects (32). ECFC pretreated
with gAcrp showed a similarly increased migratory activity
for nondiabetic age-matched control subjects (hECFC:
39.6 6 15.3% control increase) and for dmECFC (30.3 6
9.2% control increase) (Fig. 3E). Likewise, pretreatment
with parecoxib alone did not affect migratory activity,
whereas the stimulatory effect of gAcrp vanished when
combined with parecoxib. On a functional basis, simulta-
neous treatment with gAcrp and SOD compared with
gAcrp alone showed a further trend to improved migratory
activity (48.7 6 11.3% increase for gAcrp + SOD vs. 30.3 6
9.2% increase for gAcrp alone; P = 0.289).
In vivo neovascularization capacity of dmECFC is
impaired and can be rescued by gAcrp. Smadja et al.
(33) showed that cord blood-derived ECFC are capable of
enhancing neovascularization in an in vivo hind limb is-
chemia model, but data for hECFC and dmECFC were still
lacking. Therefore, we set out to evaluate whether ECFC
from nondiabetic donors and patients with type 2 diabetes
are capable of enhancing neovascularization in a normo-
glycemic nu/nu mouse hind limb ischemia model as the
most permissive environment (Fig. 4A). Indeed, we ob-
served that nondiabetic age-matched controls (hECFC)
signiﬁcantly (P , 0.05) enhance hind limb perfusion (rel-
ative blood ﬂow in ischemic vs. nonischemic hind limb;
60.9 6 10.1% for hECFC vs. 20.1 6 7.5% for untreated
control) (Fig. 4B and C). Consistent with the above in vitro
data, dmECFC-treated animals also showed augmented
blood ﬂow; however, the difference did not reach a level of
statistical signiﬁcance relative to control because of their
reduced in vivo neovascularization capacity (relative
blood ﬂow: 34.9 6 6.6% in dmECFC vs. 20.1 6 7.5% in
untreated control) (Fig. 4B and C).
Next, we evaluated the in vivo relevance of our in vitro
pretreatment protocol using gAcrp. Pretreated dmECFC
signiﬁcantly facilitated hind limb perfusion (relative
blood ﬂow: 65.2 6 5.1%, P , 0.01) versus control
dmECFC. The effects of gAcrp-pretreated dmECFC no
longer differed from those observed for hECFC (P =0 . 6 7 )
(Fig. 4B and C).
Preconditioning effects of gAcrp are maintained in
hyperglycemia. Because a hyperglycemic environment
has been shown to negatively affect endothelial progeni-
tors in vitro (15,17), we further assessed whether the in
vivo neovascularization capacity of ECFC pretreatment
with gAcrp is sustained in a hyperglycemic environment
in vivo (Fig. 5A). We observed consistent treatment effects
as seen in the normoglycemic hind limb ischemia model.
Although untreated control animals showed poor hind limb
perfusion after ischemia (relative perfusion: 18.5 6 2.5%),
the administration of untreated dmECFC improved rela-
tive limb perfusion to 45.3 6 5.5% (P , 0.05 vs. control)
(Fig. 5B). Most important, animals showed even further
and signiﬁcant improvements in limb perfusion after in-
fusion of dmECFC that were pretreated with gAcrp
(71.8 6 2.9%, P , 0.05 vs. control, P , 0.05 vs. untreated
dmECFC). Thus, gAcrp-pretreated dmECFC restore the
drastically impaired blood ﬂow in an ischemic hind limb
model, an effect that also persists in a clinically most rel-
evant hyperglycemic environment.
DISCUSSION
We provide evidence for the salutary effects of gAcrp on
number and function of EPC derived from patients with
type 2 diabetes. We found that gAcrp-pretreated ECFC are
more suitable for cell therapy compared with their un-
treated dysfunctional counterparts. Most strikingly, these
effects were observed in vivo both under nondiabetic
conditions and in the hyperglycemic environment of di-
abetic mice. On the basis of the presented data, we estab-
lished gAcrp pretreatment for diabetic patient-derived ECFC
as a novel way of tailored cell optimization before their use
for autologous cell therapy.
Impaired proliferation and function of EPC in patients
with type 2 diabetes has been described (16,34–36).
Ingram et al. (17) provided the ﬁrst evidence that cord
blood-derived ECFC from newborns of mothers with ges-
tational diabetes also displayed lower proliferation rates
and reduced neovascularization potency both in vitro and
in vivo. Our experiments further emphasize these ﬁndings
and add new evidence for an impairment of peripheral
blood-derived ECFC in adult patients. Indeed, we observed
a reduced proliferation rate of dmECFC in vitro and, more
important, a reduced neovascularization capacity in vivo
compared with nondiabetic ECFC. Therefore, optimization
strategies are absolutely crucial for the clinical use of
these cells in an autologous setting.
In 1995, Scherer et al. (37) ﬁrst described a serum pro-
tein similar to the complement component C1q that is
produced exclusively in adipocytes and then introduced it
as adipocyte complement-related protein of 30 kDa
(Acrp30), which was later termed “adiponectin.” Several
studies demonstrated a correlation between adiponectin
and type 2 diabetes mellitus. Hotta et al. (18) found lower
serum adiponectin levels in patients with type 2 diabetes
compared with BMI-matched control subjects. Reciprocally,
people with high serum concentrations seem to have
a lower risk of developing diabetes (19,20), and increasing
adiponectin concentrations seem to minimize chances to
develop insulin resistance and type 2 diabetes (21–23).
Only recently, Shibata et al. (38) demonstrated a correlation
between adiponectin levels and the number of blood-borne
early EPC. In addition, they also reported a beneﬁcial effect
of adiponectin on the number of early EPC in vitro. Stim-
ulatory effects of adiponectin have also been shown on
hematopoietic stem cells, osteoblasts, and mesangioblasts
(38–41). In the current study, we now describe for the ﬁrst
time a strong effect of gAcrp pretreatment on highly pu-
riﬁed ECFC before their administration in ischemic models
in vivo.
Shibata et al. (42) demonstrated a protective effect of
adiponectin for myocardial ischemia–reperfusion injury
mediated by inhibition of apoptosis through AMP-activated
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treatment with dmECFC or hECFC in a normoglycemic NMRI nu/nu model. B: Quantiﬁcation of hind limb perfusion after injection of dmECFC
treated with gAcrp in the presence or absence of parecoxib compared with hECFC (*P < 0.05 vs. control, P < 0.05 vs. dmECFC, **P < 0.05 vs.
gAcrp, n =4 –8). C: Representative pictures from hind limb perfusion measurements, as assessed by indocyanine green injection. Arrows indicate
the ischemic hind limb. Relative perfusion between ischemic and nonischemic hind limbs is given in percent. (A high-quality digital representation
of this ﬁgure is available in the online issue.)
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through COX-2–dependent pathways. In addition, stromal
cells and lymphocyte precursors are inﬂuenced by adipo-
nectin through the COX-2 pathway (30). Moreover, we
recently demonstrated that prostaglandin E1 and PGE2
stimulate progenitor cell proliferation and function through
induction of eNOS (31). Consequently, we postulated that
the observed effects of gAcrp are primarily mediated
through induction of COX-2, followed by a consecutive
increase of PGE2 secretion and eNOS expression leading
to enhanced ECFC proliferation and, most important,
improved function. Indeed, inhibition of the COX-2
pathway virtually abrogated adiponectin-induced effects
on ECFC.
Of note, not only the native proliferation of dmECFC
was impaired in comparison with nondiabetic ECFC but
also the gAcrp-mediated increase in proliferation was less
pronounced in dmECFC. Oxidative stress has been iden-
tiﬁed as one of the major obstacles for progenitor cell
proliferation by forcing them into senescence (43). By
expressing antioxidative enzymes at high levels, in par-
ticular SOD, progenitor cells are usually well protected
against oxidative stress (44). Still, Ceradini et al. (45)
demonstrated in a streptozotocin-induced diabetes murine
model that mobilization and migratory activity of bone
marrow-derived EPC are vastly reduced because of oxi-
dative stress. Addition of SOD was able to reverse the
observed negative effects. Consistently, we now show that
gAcrp-enhanced dmECFC cell numbers can be further
increased by subsidiary addition of SOD. Nevertheless,
gAcrp alone already showed a signiﬁcant increase in cell
number, which is supported by other antioxidative fea-
tures of adiponectin, as previously shown (46), and was
sufﬁcient to generate strong in vivo cell therapeutic
effects. In line with these data, our study clearly demon-
strates that gAcrp treatment reduces reactive oxygen levels
in diabetic ECFC. Moreover, strong invasive character-
istics, which can be assessed in vitro as cell migration in a
FIG. 5. Perfusion in a diabetic hind limb ischemia model after dmECFC pretreatment with gAcrp. A: NMRI n/n were treated according to the low-
dose streptozotocin protocol of the Animal Models of Diabetic Complications Consortium to create hyperglycemia before hind limb surgery. B:
Relative perfusion as assessed by O2C laser Doppler measurements in hyperglycemic mice (*P < 0.05 vs. control; **P < 0.05 vs. dmECFC, n =3 –6).
After 2 weeks, hind limb perfusion was measured via laser Doppler in both the ischemic and nonischemic legs. STZ, streptozotocin.
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features mandatory for systemically infused progenitor
cells to invade the ischemic tissue. Notably, gAcrp treat-
ment of dmECFC alone also provoked a marked increase
in migratory activity that was comparable to that observed
in nondiabetic ECFC. This increased migratory activity
could be further enhanced by simultaneous treatment
with SOD, though not on a statistically signiﬁcant level.
gAcrp-pretreated dmECFC signiﬁcantly improved neo-
vascularization in a murine hind limb ischemia model,
whereas untreated dmECFC showed inferior results with
respect to neovascularization improvements. These data
suggest that, although proliferation of dmECFC is still
limited by oxidative stress, gAcrp pretreatment still leads
to a robust functional restoration of dmECFC leading to
strong in vivo regenerative activity.
One may speculate that reexposure of gAcrp-pretreated
ECFC to a hyperglycemic environment reverses the gained
function of ECFC via aforementioned or yet unknown
mechanisms. A recently published study of Eren et al. (47)
studied the question whether the success of vascular cell
therapy relies on adiponectinemia in the cell donor or in
the cell recipient. The authors concluded that adipo-
nectinemia in the recipient is essential for the proangio-
genic effects of cell therapy. These data suggest that
adiponectin-pretreated dmECFC might be ineffective in
a hyperglycemic environment associated with depressed
adiponectin blood levels. However, our data clearly show
that optimization of vascular cell therapy with adiponectin
indeed withstands an unfavorable hyperglycemic envi-
ronment in vivo.
In conclusion, we demonstrate for the ﬁrst time that
treatment effects of ex vivo gAcrp pretreatment of ECFC
are preserved even after retransfer of dmECFC to a hy-
perglycemic environment. We demonstrate feasibility and
efﬁcacy of an ex vivo pretreatment protocol aiming for
progenitor cell optimization before their use for cell ther-
apy. Furthermore, our present data corroborate our pre-
vious ﬁndings regarding the importance of the COX-2
pathway for the neovascularization capacity of isolated
ECFC (31), and we thus provide important new data that
the activation of the COX-2 pathway, which can safely be
achieved by gAcrp administration, may be a major target
for future EPC optimization strategies.
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